| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PXMD | Common Stock | Sale | -$190 | -185 | -0.72% | $1.03* | 25.7K | Nov 27, 2023 | Direct | F1, F2, F4 |
| holding | PXMD | Common Stock | 432K | Nov 27, 2023 | TardiMed Sciences, LLC | F3, F4 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan to, inter alia, pay tax withholding on vested RSUs. |
| F2 | The sale price represents the weighted average sale price of the shares sold ranging from $0.97 to $1.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| F3 | The reporting person is the managing partner of TardiMed Sciences, LLC and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| F4 | Reflects a 1-for-17 reverse stock split effective October 30, 2023. |